Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice.

@article{Cummings1996PharmacokineticsMA,
  title={Pharmacokinetics, metabolism and tumour disposition of 8-chloroadenosine 3',5'-monophosphate in breast cancer patients and xenograft bearing mice.},
  author={Jeffrey Wayne Cummings and Simon P. Langdon and Alison A. Ritchie and David J Burns and John Seton Mackay and Peter Stockman and Robert C. F. Leonard and William R Miller},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={1996},
  volume={7 3},
  pages={
          291-6
        }
}
BACKGROUND 8-Chloroadenosine 3',5'-monophosphate (8-Cl-cAMP) is undergoing phase I clinical trials as an anticancer drug. However, there is debate as to whether it is a prodrug for its 8-Cl-adenosine metabolite. DESIGN Pharmacokinetics, metabolism and tumour disposition studies have been performed in 7 breast cancer patients receiving continuous infusion (28 day) 8-Cl-cAMP (0.54 or 1.08 mg/kg/day) and tumour biopsies were obtained before and on the last day of infusion. Parallel studies were… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells.

  • Cancer research
  • 2001
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats

  • Cancer Chemotherapy and Pharmacology
  • 2002
VIEW 2 EXCERPTS
CITES BACKGROUND

Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications.

  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2000
VIEW 1 EXCERPT
CITES BACKGROUND